<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03302234</url>
  </required_header>
  <id_info>
    <org_study_id>3475-598</org_study_id>
    <secondary_id>2016-004364-20</secondary_id>
    <secondary_id>MK-3475-598</secondary_id>
    <nct_id>NCT03302234</nct_id>
  </id_info>
  <brief_title>Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer (MK-3475-598/KEYNOTE-598)</brief_title>
  <official_title>A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors Are PD-L1 Positive (TPS ≥ 50%) (KEYNOTE-598)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of pembrolizumab given in combination
      with either ipilimumab or placebo as first-line treatment in participants with metastatic
      non-small cell lung cancer (NSCLC). The primary hypothesis of this study is that overall
      survival (OS) and/or progression-free survival (PFS) is prolonged in participants who receive
      pembrolizumab and ipilimumab compared to those who receive pembrolizumab and placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2017</start_date>
  <completion_date type="Anticipated">February 22, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>OS is the time from randomization to death due to any cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>PFS is the time from randomization to first documented disease progression per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>ORR is the proportion of the participants who achieve complete response (CR) or partial response (PR) per RECIST 1.1 by BICR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration Of Response (DOR)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>DOR is the time from first documented evidence of CR or PR per RECIST 1.1 by BICR until disease progression per RECIST 1.1 by BICR or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to True Deterioration (TTD) in Cough, Pain in Chest, and Shortness of Breath</measure>
    <time_frame>On study day 1 prior to initiation of study therapy (baseline) and up to approximately 2 years</time_frame>
    <description>Time to true deterioration is defined as the time to the first onset of a 10-point or greater score decrease from study day 1 prior to initiation of study therapy (baseline) in any one of the 3 symptoms, confirmed by a second adjacent 10-point or greater score decrease from baseline. Cough is based on European Organization for Research and Treatment of Cancer Quality of Life Questionnaire and Lung Cancer Module 13 (EORTC QLQ-LC13) question 1, pain in chest is based on EORTC QLQ-LC13 question 10, and shortness of breath is based on European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) question 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>From time of signing the informed consent form (ICF) until the end of follow-up (up to approximately 118 Weeks).</time_frame>
    <description>Percentage of participants experiencing any unfavorable and unintended sign, symptom, disease, or worsening of pre-existing condition temporally associated with study therapy and irrespective of causality to study therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Discontinuations</measure>
    <time_frame>From time of signing the ICF until the end of study therapy (up to approximately 105 Weeks).</time_frame>
    <description>Percentage of participants discontinuing study drug due to an AE.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">548</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>pembrolizumab + ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 200 mg of pembrolizumab by intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus 1 mg/kg of ipilimumab by IV infusion on Day 1 of each 6-week cycle for up to 18 cycles of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pembrolizumab + placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive 200 mg of pembrolizumab by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus placebo by IV infusion on Day 1 of each 6-week cycle for up to 18 cycles of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pembrolizumab</intervention_name>
    <description>Administered as an intravenous (IV) infusion every 3 weeks (Q3W)</description>
    <arm_group_label>pembrolizumab + ipilimumab</arm_group_label>
    <arm_group_label>pembrolizumab + placebo</arm_group_label>
    <other_name>KEYTRUDA®</other_name>
    <other_name>MK-3475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ipilimumab</intervention_name>
    <description>Administered as an IV infusion every 6 weeks (Q6W)</description>
    <arm_group_label>pembrolizumab + ipilimumab</arm_group_label>
    <other_name>YERVOY®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo for ipilimumab</intervention_name>
    <description>Normal saline solution administered as an IV infusion Q6W</description>
    <arm_group_label>pembrolizumab + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has a histologically or cytologically confirmed diagnosis of Stage IV metastatic NSCLC
             (American Joint Committee on Cancer version 8)

          -  Has measurable disease per RECIST 1.1 as determined by investigator

          -  Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Has a life expectancy of &gt;3 months

          -  Has provided archival tumor tissue sample or newly obtained core or excisional biopsy
             of a tumor lesion not previously irradiated

          -  Female participants of childbearing potential must have a negative serum pregnancy
             test within 72 hours prior to receiving the first dose of study therapy

          -  Female and male participants of reproductive potential must agree to use contraception
             starting from the first dose of study medication, throughout the study period, and for
             up to 120 days after the last dose of study medication

          -  Male participants must refrain from donating sperm starting from the first dose of
             study medication, throughout the study period, and for up to 120 days after the last
             dose of study medication

        Exclusion Criteria:

          -  Has received prior systemic chemotherapy/other targeted or biological antineoplastic
             therapy treatment for their Stage IV metastatic NSCLC

          -  Has a tumor that harbors an epidermal growth factor receptor (EGFR)-sensitizing
             (activating) mutation or an anaplastic lymphoma kinase (ALK) translocation

          -  Is currently participating in or has participated in a trial of an investigational
             agent or has used an investigational device within 4 weeks prior to the first dose of
             study therapy

          -  Has received prior therapy with an anti-Programmed Cell Death Receptor 1 (PD-1),
             Programmed Cell Death Receptor Ligand 1 (anti-PD-L1), or anti- Programmed Cell Death
             Receptor Ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or
             co-inhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein 4
             [CTLA-4], OX-40, CD137)

          -  Has received prior radiotherapy within 2 weeks of start of study therapy or received
             lung radiation therapy of &gt;30 Gray (Gy) within 6 months of the first dose of study
             therapy

          -  Has recovered from all radiation-related toxicities, does not require corticosteroids,
             and has not had radiation pneumonitis

          -  Is receiving systemic steroid therapy ≤7 days prior to the first dose of study therapy
             or receiving any other form of immunosuppressive medication

          -  Has a known additional malignancy that is progressing or has required active treatment
             within the past 3 years with the exception of curatively treated basal cell carcinoma
             of the skin, squamous cell carcinoma of the skin and/or curatively resected in situ
             cancers

          -  Has known untreated central nervous system (CNS) metastases and/or carcinomatous
             meningitis

          -  Has an active autoimmune disease that has required systemic treatment in past 2 years
             (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive
             drugs)

          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
             (i.e., doses exceeding 10 mg daily of prednisone equivalent) or any other form of
             immunosuppressive therapy within 7 days prior the first dose of study therapy

          -  Has a history of (non-infectious) pneumonitis that required systemic steroids or
             current pneumonitis/interstitial lung disease

          -  Has had an allogeneic tissue/solid organ transplant

          -  Has received a live vaccine within 30 days prior to the first dose of study therapy

          -  Has an active infection requiring systemic therapy

          -  Has a known history of human immunodeficiency virus (HIV) infection

          -  Has a known history of hepatitis B or known active hepatitis C virus infection

          -  Has a known history of active tuberculosis

          -  Has known psychiatric or substance abuse disorders that would interfere with
             cooperating with the requirements of the trial

          -  Is a regular user of any illicit drugs or had a recent history of substance abuse

          -  Is pregnant or breast feeding or expecting to conceive or father starting from the
             first dose of study medication, throughout the study period, and for up to 120 days
             after the last dose of study medication

          -  Has severe hypersensitivity to pembrolizumab and/or any of its excipients and/or to
             ipilimumab and/or any of its excipients

          -  Has a ROS1 translocation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pacific Cancer Care ( Site 0001)</name>
      <address>
        <city>Monterey</city>
        <state>California</state>
        <zip>93940</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>831-375-4105</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Wayne Cancer Clinic at Providence Saint John's Hospital ( Site 0021)</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>310-582-7249</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paducah Cancer &amp; Blood Center ( Site 0018)</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>270-441-4343</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>New England Cancer Specialists ( Site 0019)</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>207-396-7600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lahey Hospital &amp; Medical Center ( Site 0020)</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>781-744-2815</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center ( Site 0016)</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>614-366-1554</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Greenville Health System ( Site 8010)</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-863-4631</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Erlanger Oncology &amp; Hematology ( Site 0026)</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>423-778-2167</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tennessee Cancer Specialists ( Site 0017)</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>865-934-2670</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Arlington South ( Site 8006)</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-863-4631</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Methodist Dallas Cancer Center ( Site 8000)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-863-4631</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Flower Mound ( Site 8007)</name>
      <address>
        <city>Flower Mound</city>
        <state>Texas</state>
        <zip>75028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>916-533-0052</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Longview Cancer Center ( Site 8009)</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-863-4631</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, P.C. ( Site 8001)</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>281-863-4631</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Carbone Cancer Center ( Site 0004)</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>608-263-9063</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanatorio Parque ( Site 0201)</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+543414200250</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Aleman ( Site 0208)</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5411482770002306</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Privado Centro Medico Cordoba ( Site 0206)</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+543514862400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico Riojano Integral ( Site 0203)</name>
      <address>
        <city>La Rioja</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+549384693919</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto de Oncologia de Rosario ( Site 0200)</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+543414218909</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Medico San Roque ( Site 0207)</name>
      <address>
        <city>Tucuman</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+543814306987</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Clinicas - Clinica Viedma ( Site 0202)</name>
      <address>
        <city>Viedma</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+542920428700170</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chris OBrien Lifehouse ( Site 2100)</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61285140922</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Townsville Hospital ( Site 2103)</name>
      <address>
        <city>Douglas</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61744331671</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Vincents Hospital Melbourne ( Site 2101)</name>
      <address>
        <city>Fitzroy</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61392313156</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIUSSS du Saguenay-Lac-St-Jean ( Site 0115)</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>H9H 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>41854112342840</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIUSSS Ouest de l'Ile - St-Mary's Hospital ( Site 0107)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H9H 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>51434535113981</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St-Jerome Medical Research Inc ( Site 0113)</name>
      <address>
        <city>St-Jerome</city>
        <state>Quebec</state>
        <zip>H9H 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>450431102042</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional del Cancer ( Site 0406)</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56998860485</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pontificia Universidad Catolica de Chile ( Site 0404)</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56223547919</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soc. Prosalud Montes y Orlandi Ltda (Orlandi Oncologia) ( Site 0401)</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56992214787</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad Catolica del Maule ( Site 0413)</name>
      <address>
        <city>Talca</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56981340385</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Vina del Mar ( Site 0400)</name>
      <address>
        <city>Vina del Mar</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56322204521</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Nord du Marseille ( Site 0808)</name>
      <address>
        <city>Marseille</city>
        <state>Cedex 20</state>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33491965901</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie ( Site 0803)</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33556333229</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Brest. Hopital Morvan ( Site 0800)</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33298223274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hopitalier Intercommunal Creteil ( Site 0802)</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33157022070</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Le Mans ( Site 0804)</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33243432764</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>C.H.R.U de Lille - Hopital Calmette ( Site 0805)</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33320444998</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon ( Site 0810)</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33156016531</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nouvel Hopital Civil ( Site 0809)</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33369550905</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse - Hopital Larrey ( Site 0801)</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33567771837</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Emil von Behring ( Site 0905)</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+493081021447</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Spandau ( Site 0910)</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4930130132601</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Heidelberg ( Site 0900)</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4962213961304</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Leipzig ( Site 0919)</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+493419712600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orszagos Koranyi TBC es Pulmonologiai Intezet ( Site 1502)</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36302005233</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orszagos Koranyi TBC es Pulmonologiai Intezet ( Site 1506)</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36703102318</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orszagos Onkologiai Intezet ( Site 1509)</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36303384465</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Veszprem Megyei Tudogyogyintezet ( Site 1503)</name>
      <address>
        <city>Farkasgyepu</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3689358013</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Petz Aladar Megyei Oktato Korhaz ( Site 1505)</name>
      <address>
        <city>Gyor</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36309758356</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bekes Megyei Pandy Kalman Korhaz. ( Site 1507)</name>
      <address>
        <city>Gyula</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36704533531</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz ( Site 1504)</name>
      <address>
        <city>Szekesfehervar</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3622535722</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 1501)</name>
      <address>
        <city>Szolnok</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36209323256</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital ( Site 1312)</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+35318092082</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Limerick ( Site 1403)</name>
      <address>
        <city>Limerick</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+35361482013</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Casa Sollievo della Sofferenza ( Site 1009)</name>
      <address>
        <city>San Giovanni Rotondo (FG)</city>
        <state>Foggia</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390882410640</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Humanitas Research Hospital ( Site 1004)</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390282244080</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Mater Salutis ( Site 1005)</name>
      <address>
        <city>Legnago</city>
        <state>Verona</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390442632418</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Spedali Civili ( Site 1001)</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390303996537</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia ( Site 1007)</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390257489440</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Gerardo ASST Monza ( Site 1002)</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390392339354</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AORN dei Colli Plesso Monaldi ( Site 1003)</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390817064300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria della Misericordia ( Site 1008)</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+393384569353</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center ( Site 2302)</name>
      <address>
        <city>Seoul</city>
        <zip>4130</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82230403214</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center ( Site 2301)</name>
      <address>
        <city>Seoul</city>
        <zip>4130</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82234103450</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital ( Site 2303)</name>
      <address>
        <city>Seoul</city>
        <zip>4130</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>8220722228</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pauls Stradins Clinical University Hospital ( Site 1100)</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+37167069457</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Riga East Clinical University Hospital ( Site 1111)</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+37126594570</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Especializado de Enfermedades Neoplasicas SRL-CEEN SRL ( Site 0710)</name>
      <address>
        <city>Arequipa</city>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+51959617508</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Regional de Enfermedades Neoplasicas del Sur IRENSUR ( Site 0704)</name>
      <address>
        <city>Arequipa</city>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+51992753316</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Internacional Sede San Borja ( Site 0701)</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+51999611475</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional Cayetano Heredia ( Site 0706)</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+51953838268</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Peruano Americana ( Site 0703)</name>
      <address>
        <city>Trujillo</city>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+51943529090</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Wojewodzki w Koszalinie im. Mikolaja Kopernika ( Site 1614)</name>
      <address>
        <city>Koszalin</city>
        <state>Zachodniopomorskie</state>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48943488400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 1609)</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48501446778</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Przychodnia Lekarska Komed ( Site 1602)</name>
      <address>
        <city>Konin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48664134814</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc ( Site 1607)</name>
      <address>
        <city>Olsztyn</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>48513197853</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie ( Site 1600)</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48225463066</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr G.A. Landers Specialist Oncologist ( Site 1803)</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27312099030</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sandton Oncology Medical Group PTY LTD ( Site 1807)</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27118830900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol ( Site 1207)</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34934978925</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Insular de Gran Canaria ( Site 1203)</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>Gran Canaria</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34928441738</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Duran i Reynals ( Site 1201)</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34932607744</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d Hebron ( Site 1211)</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+349327460004823</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcantara ( Site 1208)</name>
      <address>
        <city>Caceres</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34927621612</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Fundacion Jimenez Diaz - Clin. Concepcion ( Site 1209)</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34915504800253900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio ( Site 1200)</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34955013068</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation - Kaohsiung ( Site 2404)</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+88677317123X3246</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital. ( Site 2403)</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886422052121</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital ( Site 2401)</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+88662353535X4289</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital ( Site 2400)</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886223123456</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital - Linkou Branch ( Site 2402)</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886332812008468</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ramathibodi Hospital. ( Site 2563)</name>
      <address>
        <city>Ratchthevee</city>
        <state>Bangkok</state>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6622011671</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chulalongkorn Hospital ( Site 2561)</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6622564533</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pramongkutklao Hospital ( Site 2564)</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6623547600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital ( Site 2562)</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6624194488</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Khon Kaen University ( Site 2565)</name>
      <address>
        <city>Khon Kaen</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6643366564</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ege Universitesi Tip Fakultesi Hastanesi ( Site 1901)</name>
      <address>
        <city>Izmir</city>
        <state>Bornova</state>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+902323902910</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acibadem Adana Hastanesi ( Site 1904)</name>
      <address>
        <city>Adana</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+90526710541</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ankara Ataturk EAH ( Site 1903)</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905555306271</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 1908)</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+9031230543304336</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uludag Universitesi Tip Fakultesi ( Site 1914)</name>
      <address>
        <city>Bursa</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905327183896</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Trakya Uni. Tip Fakultesi ( Site 1911)</name>
      <address>
        <city>Edirne</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905322480998</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 1906)</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905057452605</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi ( Site 1912)</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905425150897</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Park Izmir Hospital ( Site 1900)</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905322642353</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kocaeli Universitesi Tip Fakultesi ( Site 1909)</name>
      <address>
        <city>Kocaeli</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905327650185</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inonu Universitesi Tip Fakultesi ( Site 1907)</name>
      <address>
        <city>Malatya</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905326441884</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karadeniz Teknik Universitesi ( Site 1910)</name>
      <address>
        <city>Trabzon</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+904623252819</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MI Kryviy Rih Center of Dnipropetrovsk Regional Council ( Site 2005)</name>
      <address>
        <city>Kryviy Rih</city>
        <state>Dnipropetrovsk Region</state>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380675393937</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Onco Dispensary_ State Medical University ( Site 2012)</name>
      <address>
        <city>Chernivtsy</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380372577671</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dnipropetrovsk City Multidiscipline Clinical Hosp.4 of DRC ( Site 2000)</name>
      <address>
        <city>Dnipropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380675625054</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MI Prykarpatskyi Clinical Oncology Centrum ( Site 2009)</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380502094000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>PP PPC Acinus Medical and Diagnostic Centre ( Site 2002)</name>
      <address>
        <city>Kropyvnytsky</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380667103410</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyiv City Clinical Oncological Center ( Site 2014)</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380503512896</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute of the MoH of Ukraine ( Site 2015)</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380509095151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lviv State Oncology Regional Treatment and Diagnostic Centre ( Site 2003)</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380505136507</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MI Odessa Regional Oncological Centre ( Site 2004)</name>
      <address>
        <city>Odesa</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380504261911</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Georges University Hospital NHS Foundation Trust ( Site 1321)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+440287252970</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Cancer Centre ( Site 1307)</name>
      <address>
        <city>Northwood</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441438284298</phone>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>Mexico</country>
    <country>Russian Federation</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2017</study_first_submitted>
  <study_first_submitted_qc>October 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2017</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Programmed Cell Death Receptor 1 (PD-1)</keyword>
  <keyword>Programmed Cell Death Receptor Ligand 1 (PD-L1)</keyword>
  <keyword>Cytotoxic T-lymphocyte-associated protein 4 (CTLA4)</keyword>
  <keyword>PD1</keyword>
  <keyword>PD-1</keyword>
  <keyword>PDL1</keyword>
  <keyword>PD-L1</keyword>
  <keyword>CTLA4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

